SCHEMBL12440840

SCHEMBL12440840

CN(CCn1cc(-c2cncc(-c3cc(-c4cc(Cl)ccc4F)nc4ncccc34)c2)cn1)C(=O)OC(C)(C)C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACACB O00763 1/20 0.37
ACACA Q13085 1/20 0.37
TGFBR1 P36897 6/20 0.36
MAP4K4 O95819 2/20 0.36
ACVR1B P36896 2/20 0.34
ACVRL1 P37023 2/20 0.34
HCRTR1 O43613 1/20 0.34
HCRTR2 O43614 1/20 0.34
HTR2C P28335 1/20 0.33
SLC6A4 P31645 1/20 0.33
IDO1 P14902 2/20 0.33
PDK2 Q15119 2/20 0.33
SCN9A Q15858 1/20 0.32
MAPK1 P28482 1/20 0.32
KAT6A Q92794 1/20 0.32
KAT5 Q92993 1/20 0.32
CCNC P24863 2/20 0.32
CDK8 P49336 2/20 0.32
FLT3 P36888 1/20 0.32
MYLK Q15746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12439725 0.94 ACACB (0.34) ACACBACACATGFBR1MAP4K4ACVR1B
SCHEMBL12440047 0.86 TGFBR1 (0.46) TGFBR1MAP4K4IDO1CDK8MET
SCHEMBL13968476 0.84 CYP3A4 (0.41)
SCHEMBL2325058 0.84 TGFBR1 (0.41) TGFBR1MAP4K4IDO1FLT3MET
SCHEMBL2327513 0.82 MET (0.42) TGFBR1PDK2MET
SCHEMBL12440044 0.82 FEN1 (0.43) TGFBR1MAP4K4MAPK1
SCHEMBL12439726 0.82 TGFBR1 (0.41) TGFBR1MAP4K4IDO1CDK8MET
SCHEMBL12440841 0.80 TGFBR1 (0.36) TGFBR1MAP4K4IDO1MAPK1MET
SCHEMBL13968445 0.80 TGFBR1 (0.45) TGFBR1MAP4K4HCRTR1HCRTR2MET
SCHEMBL13968474 0.78 KDR (0.36) TGFBR1MAP4K4ACVRL1MAPK1CCNC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8912216-B2 Hetaryl-[1,8]naphthyridine derivatives MERCK PATENT GMBH (DE) 2014-12-16 US disclosed
US-8912216-B2 Hetaryl-[1,8]naphthyridine derivatives MERCK PATENT GMBH (DE) 2014-12-16 US disclosed
US-20140038960-A1 Hetaryl-[1,8]naphthyridine derivatives MERCK PATENT GMBH (DE) 2014-02-06 US disclosed
US-20140038960-A1 Hetaryl-[1,8]naphthyridine derivatives MERCK PATENT GMBH (DE) 2014-02-06 US disclosed
US-20120295902-A1 Hetaryl-[1,8]naphthyridine derivatives MERCK PATENT GMBH (DE) 2012-11-22 US disclosed
US-20120295902-A1 Hetaryl-[1,8]naphthyridine derivatives MERCK PATENT GMBH (DE) 2012-11-22 US disclosed
WO-2011095196-A1 HETARYL-[1,8]NAPHTHYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2011-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140038960-A1 Hetaryl-[1,8]naphthyridine derivatives ATP5F1A, ATP5ME, ATP5F1D ACACB 2238/4885ACACA 2172/4885TGFBR1 2919/4885
US-20120295902-A1 Hetaryl-[1,8]naphthyridine derivatives ATP5F1A, ATP5ME, ATP5F1D ACACB 2238/4885ACACA 2172/4885TGFBR1 2919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.